Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1Carcinoma, Basal Cell 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 35Cisplatin 21Capecitabine 17Oxaliplatin 16Leucovorin 11Fluorouracil 11pembrolizumab 8S 1 (combination) 8Nivolumab 6tremelimumab 5durvalumab 5Bevacizumab 5lenvatinib 4Irinotecan 4trametinib 3titanium silicide 3atezolizumab 3Radiofrequency Ablation 3zanidatamab 2vandetanib 2irinotecan sucrosofate 2derazantinib 2camrelizumab 2binimetinib 2apatinib 2Trastuzumab 2Tegafur 2Radiotherapy 2Panitumumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Biliary Tract Neoplasms × silmitasertib × Clear all
NCT02128282 2021-10-22

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Senhwa Biosciences, Inc.

Phase 1/2 Completed
127 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡